We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.00 | 1.13% | 267.50 | 266.00 | 269.50 | 273.00 | 266.50 | 266.50 | 9,662 | 14:06:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
13/10/2017 06:18 | I am sre Mark Slater will be doing the same as it now exceeds 10% in his Growth Fund | nerdofsteel | |
12/10/2017 21:49 | I had to top slice a few, it’s now well over 50% of my portfolio. Still positive, just need to divest. | rabiddog | |
12/10/2017 18:15 | Yes, and interesting that Professor Mok already holds 10,002 American Depository Shares which he may have held for some time. Clearly as a clinician and a lung cancer expert, he thinks our late stage portfolio has fanatasic potential. $20bn mcap Company within the next few years IMO. I continue to buy. | nerdofsteel | |
12/10/2017 10:54 | But of a muted response. Can't see the new director would get involved unless he was very positive and confident about the drug pipeline. Let's see how NY opens up, wouldn't be surprised if they took more notice. There cannot be many companies of this size that are so lightly traded. I get the feeling that the only people who ever sell are those who aren't allowed to have too much concentration in their portfolio. They must be cursing how the share price keeps rising! | mad foetus | |
12/10/2017 08:32 | Another all time high reached in London this morning on the back of the ADR rise last night - this is playing havoc with my target to get to a holding of 10,000 shares | nerdofsteel | |
12/10/2017 07:21 | Good assessment mad, I think you are correct, and Professor Mok's contacts and high profile in the Lung cancer world in particular, will be extremely vlaubale to the Company. I understand the Company will be presenting at the annual Stifel Healthcare Conference in November, which is attended by leading institutional investors and specialist healthcare Analaysts. | nerdofsteel | |
12/10/2017 06:38 | Heavyweight director appointed with close links to multiple Chinese universities and expertise in lung cancer. I wonder whether the stars are aligning for HCM and whether the Chinese authorities are starting to see that HCM could be the flag bearer for their pharmaceutical industry? | mad foetus | |
12/10/2017 06:00 | The number of watchers on Stocktwits Bulletin Board, which is mainly used by Private Investors and traders continues to increase | nerdofsteel | |
11/10/2017 20:43 | Closed at £47.20 on high volume (equiv of 16,000 UK shares)Roll on tomorrow, roll on news | mad foetus | |
11/10/2017 17:00 | Trading at equiv of £46.70-£47 in NYIt really looks like they are cottoning on. | mad foetus | |
10/10/2017 10:00 | There's every chance Frquinrinib could be approved by xmas or very earky in 2018, which will provide $20-$35m nett income straight to the bottom line within a few years | nerdofsteel | |
10/10/2017 07:12 | Good spots nerd, can only be positive | mad foetus | |
09/10/2017 17:06 | CFDA have just made major reforms, which include faster approval process for Chinese devloped drugs as well as foreign drugs with existing trial data This is excellent news, especially as we have a drug currently waiting approval | nerdofsteel | |
09/10/2017 16:44 | Highly stimulating video. Recommended. Thanks for posting. | reptile3 | |
09/10/2017 09:04 | hxxps://www.twst.com Tagrisso gets BT designation from the FDA in 1st line NSCLC This is VERY important news for us, as Savolitinib is trialed for use as a combination therapy with Tagrisso in 2nd and 3rd line. This must surely now assist in us and Astra getting BT designation for Savolitinib in this setting........ | nerdofsteel | |
08/10/2017 09:47 | The quantity of shares and ADR's purchased by ALL members of the Board over the last couple of years is fantastic - and they have all made major purchases using their own cash. Brilliant vote of confidence in what is one of the fastest growing Companies on the London Stock Exchange over the last 10 years. | nerdofsteel | |
06/10/2017 07:25 | Thanks. Biotech seems to be where a lot of activity is over there at moment. I think I noticed Slater was creeping over 10% on last report so risks breaking his own rules. | samsj | |
05/10/2017 19:43 | Down in the US but noticeable that the volume is about a quarter of what it was on the up days earlier in the week. Bodes well when the big moves are on big volume. | mad foetus | |
05/10/2017 14:43 | I wil consider divesting into Juno, Exelexis and Genmab as I focus mainly on Biotechs these days, it is a sector I like because of its growth, albeit with risks | nerdofsteel | |
05/10/2017 14:41 | over 30% now, I need to do some adjustments, but the 30% was due to the massive returns - my problem is now worse than Mark Slater but I have total faith in the Company and its Management..... | nerdofsteel | |
05/10/2017 09:45 | What % of portfolio Nerd if you don't mind me asking? If I'd never top-sliced this I'd be much better off, but was topping 1/3 of portfolio yesterday so sold a little again... | samsj | |
05/10/2017 06:34 | learningtrader, here is my estimate for 2025, based on the following:- Analayst forecasts of revenue and EBITDA Sector and geography P/S Sector and geography EV/EBITDA 2025 @ 16 P/S = $16,736m 2025 @ 86 EV/EBITDA = $25,800m Blended mcap = $21,268m = 5.7 x todays mcap or circa £256 per share I've been invested for 10 years, will be invested for a further 10 years and continue to buy regularly | nerdofsteel | |
05/10/2017 06:13 | You make a great point mad, they have a cash generative arm which helps fund the drug development side. Most of our peers of similar size on NASDAQ burn lots of cash with regular dilutive placements. You will also find many NASDAQ biotechs are binary e.g. They have one or two drugs only with one shot of success. | nerdofsteel | |
04/10/2017 19:26 | Learningtrader yes, will post some data tomorrow, $$20bn by 2025 based on sector P/S, EV/EBITDA etc | nerdofsteel |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions